Statute Details
- Title: Medicines (Advertisement and Sale) (Exemption) Order 2023
- Act Code: MASA1955-S819-2023
- Legislation Type: Subsidiary Legislation (SL)
- Authorising Act: Medicines (Advertisement and Sale) Act 1955
- Enacting Authority: Minister for Health
- Commencement: 18 December 2023
- Key Provisions (from extract): Sections 1–4
- Current Status: Current version as at 27 Mar 2026 (per platform status)
- Legislative Instrument Number: SL 819/2023
- Made Date: 20 November 2023
- Revokes: Medicines (Advertisement and Sale) (Exemption) Order 2004 (G.N. No. S 280/2004)
What Is This Legislation About?
The Medicines (Advertisement and Sale) (Exemption) Order 2023 (“Exemption Order”) is a short but practically significant piece of subsidiary legislation. Its core function is to carve out a specific exemption from the general advertising controls found in section 5 of the Medicines (Advertisement and Sale) Act 1955 (“1955 Act”). In plain terms, it allows certain advertisements to be published without falling within the restrictions that would otherwise apply to medicines-related advertising.
The exemption is targeted and conditional. It applies where the advertisement is published by a person who is licensed under the Healthcare Services Act 2020 (“HSA 2020”) to provide a “licensable healthcare service”. The Order therefore links the advertising regime under the 1955 Act to the licensing framework under the HSA 2020, ensuring that regulated healthcare providers can communicate about their services without being caught by the medicines advertising prohibition—at least to the extent covered by section 3 of the Exemption Order.
From a legal practitioner’s perspective, the Order is best understood as a regulatory coordination instrument. It prevents duplication or conflict between two regulatory systems: (i) the medicines advertising restrictions under the 1955 Act, and (ii) the licensing and oversight of healthcare services under the HSA 2020. The result is a narrower compliance burden for licensed healthcare providers when publishing advertisements connected to their licensable healthcare services.
What Are the Key Provisions?
Section 1 (Citation and commencement) provides the formal identity of the instrument and its effective date. The Exemption Order is cited as the “Medicines (Advertisement and Sale) (Exemption) Order 2023” and comes into operation on 18 December 2023. For compliance purposes, this matters because the exemption is not retroactive; advertisements published before commencement would not benefit from the exemption unless another legal basis applied.
Section 2 (Definition) defines the key term “licensable healthcare service”. The Order adopts the meaning given by section 3(1) of the HSA 2020. This cross-reference is important: it means the scope of the exemption depends on how the HSA 2020 defines licensable healthcare services, which in turn is shaped by the licensing categories and regulatory design of the HSA 2020. Practitioners should therefore read the HSA 2020 definition alongside this Order rather than treating “licensable healthcare service” as a self-contained concept.
Section 3 (Exemption from section 5 of Act) is the operative provision. It states that section 5 of the 1955 Act does not apply in relation to an advertisement published by a person who is licensed under the HSA 2020 to provide any licensable healthcare service. The legal effect is an exemption: the advertisement is outside the reach of section 5, provided the statutory conditions are met.
In practical terms, the exemption turns on two cumulative elements:
- Publisher condition: the advertisement must be published by a person who holds an HSA 2020 licence; and
- Service condition: the licence must be to provide any licensable healthcare service (i.e., the advertisement must be published by a licensed provider, and the provider must be licensed for the relevant licensable healthcare service category).
Although the extract does not reproduce the text of section 5 of the 1955 Act, the structure of the exemption indicates that section 5 contains a general prohibition or restriction on certain kinds of advertisements relating to medicines. The Exemption Order does not repeal section 5; rather, it specifies that section 5 is disapplied for a defined class of advertisements. This is a classic “disapplication” mechanism used in Singapore subsidiary legislation.
Section 4 (Revocation) revokes the earlier exemption order: Medicines (Advertisement and Sale) (Exemption) Order 2004 (G.N. No. S 280/2004). This means that the 2023 Order replaces the 2004 regime. For practitioners, revocation is not merely historical; it affects how to assess the legal basis for advertisements during the relevant periods. After commencement on 18 December 2023, reliance should be on the 2023 Order, not the 2004 Order.
How Is This Legislation Structured?
The Exemption Order is structured in four short sections:
- Section 1 sets out the citation and commencement date.
- Section 2 provides a definition by reference to the HSA 2020.
- Section 3 contains the substantive exemption from section 5 of the 1955 Act.
- Section 4 revokes the earlier 2004 exemption order.
There are no schedules or detailed procedural requirements in the extract. The operative legal work is done by the cross-referenced definition and the disapplication clause in section 3.
Who Does This Legislation Apply To?
The Exemption Order applies to persons who publish advertisements and who are licensed under the Healthcare Services Act 2020 to provide licensable healthcare services. In other words, it is not aimed at the general public or at all advertisers; it is aimed at a regulated subset of healthcare providers.
Because the exemption is tied to licensing status under the HSA 2020, the practical compliance question for a lawyer is whether the advertiser is (i) a licensed healthcare provider and (ii) licensed for the relevant licensable healthcare service. If the advertiser is not licensed, or if the advertisement is published by an entity that does not hold the relevant HSA 2020 licence, the exemption will not apply and section 5 of the 1955 Act may remain relevant.
Why Is This Legislation Important?
Even though the Exemption Order is brief, it can have meaningful consequences for healthcare providers’ marketing and communications strategies. Advertising is a high-risk area in regulated industries because it can trigger statutory prohibitions, enforcement action, and reputational harm. By disapplying section 5 of the 1955 Act for advertisements published by HSA-licensed providers, the Order provides a targeted compliance safe harbour—reducing uncertainty for licensed healthcare services.
From an enforcement and regulatory coordination standpoint, the Order reflects a policy choice: where a provider is already licensed and supervised under the HSA 2020, the medicines advertising restriction in the 1955 Act should not automatically apply to its advertisements about licensable healthcare services. This helps avoid duplicative regulation and supports a coherent regulatory framework.
For practitioners advising clients, the key takeaway is that the exemption is conditional and licence-dependent. Lawyers should therefore conduct (and document) licensing checks under the HSA 2020 before advising that section 5 of the 1955 Act is disapplied. Additionally, because the Order revokes the 2004 exemption order, practitioners should ensure that advice is aligned to the correct legal instrument for the relevant time period.
Finally, the cross-reference to the HSA 2020 definition of “licensable healthcare service” means that changes in the HSA 2020 licensing framework could indirectly affect the practical scope of the exemption. While the Exemption Order itself is stable, its operational meaning may evolve as the HSA 2020 regime develops.
Related Legislation
- Medicines (Advertisement and Sale) Act 1955 (particularly section 5, which is disapplied by section 3 of this Order)
- Healthcare Services Act 2020 (particularly section 3(1), which defines “licensable healthcare service”)
- Medicines (Advertisement and Sale) (Exemption) Order 2004 (revoked by section 4 of this Order)
Source Documents
This article provides an overview of the Medicines (Advertisement and Sale) (Exemption) Order 2023 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.